Ana I. Velázquez Mañana, MD, MSc, FASCO (@AnaVManana) ranks #18 among US lung cancer KOLs on X in 2026, by engagement from fellow physicians. 14 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: RASolute 302, HARMONi-6, KRASCENDO-1. CMS Open Payments lists $46,811 in 2025 general payments.
At a Glance
- 9 posts naming a trial in 2026
- 7 trials discussed by name
- Lung Cancer: US #18, Global #41 · 14 physicians engaged
- Presented at WCLC 2026 in 2026
- CMS Open Payments lists $46,811 in 2025 general payments.
This Month
What Ana I. Velázquez Mañana, MD, MSc, FASCO has posted in the last 30 days. Updated November 10, 2026.
✨ PRACTICE CHANGING ✨ data from #ESMO26 Divarasib becomes the NEW Standard of Care for 2L KRAS G12C #LungCancer @FSkoulidis presents results from Krascendo 1 Divarasib significantly prolongs PFS and OS with a more tolerable safety profile https://t.co/JAcDUqlyDi
On Monday I told a patient with SCLC, this is the treatment plan today, but I’m hoping next week I can bring you better news from #ESMO26 👇 THIS is what we are here for! 🌟 PRACTICE CHANGING update for ES-SCLC: adding tarlatamb to maintenance durvalumab increases median OS by 58% (9mo) 🌟 Congrats to @sands_jacob and to all the DeLLphi-305 investigators! #ESMO26 #LCSM
👑 Updates on ctDNA data from the CROWN study, lorlatinib in ALK-fusion positive NSCLC at #ESMO26 🔹 TP53 mut. enriched on pts who experienced early progression 🔹 Baseline TP53 mut. associated with poor prognosis 🔹 Baseline detectable ctDNA and clearance at 4 and 24 wks prognostic of PFS #LCSM
Who Amplifies Ana I. Velázquez Mañana, MD, MSc, FASCO
Physicians who reposted Ana I. Velázquez Mañana, MD, MSc, FASCO’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Lung Cancer | #18 | #41 | 14 | 17 | Full ranking |
From the Podium, 2025–26
Talks, posters and sessions Ana I. Velázquez Mañana, MD, MSc, FASCO presented at SABCS 2025 and 2026 meetings, each confirmed by a public source.
- WCLC 2026 · PresentationStudy on screening lung cancer patients for social unmet needsSource: @FionnualaCrowle on X ↗
- WCLC 2026 · Invited lectureDebate, IASLC workshop on global communication (How to Get your Message across in an Age of Ceaseless Noise)Source: @StephenVLiu on X ↗
What Colleagues Are Saying About Ana I. Velázquez Mañana, MD, MSc, FASCO
2026 posts by fellow physicians that mention @AnaVManana, quoted word for word.
No better way to start a visit to the Madrid that with lunch with my onc sisters @AnaVManana and @ShrutiPatelMD #ESMO26 https://t.co/jBnlmvw3XR
🎉👏👏Congratulations to @AnaVManana @UCSF and @JackieAredoMD @StanfordCancer @LatinasInMed named among the 40 under 40 in Cancer Awardees during #ASCO26. 2026 Class of 40 Under 40 in Cancer to Be Honored During ASCO https://t.co/iy04OsbXSD
Join us at #WCLC26 on Saturday, September 12 at 2PM KST for this workshop on global communication. Chaired by @MattSmeltzer @HegiFiona with global perspective from Caicun Zhou and a fun debate between @AnaVManana and me! https://t.co/0q7CaZ2aMu
Important study presented by @AnaVManana- outside the exam room our patients have many social unmet needs which affect outcomes. Can’t address these needs if we don’t screen for them. #WCLC26 https://t.co/Sdt0vo950l
Trials Ana I. Velázquez Mañana, MD, MSc, FASCO Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| RASolute 302 | 2 | #22 of 73 | May 31, 2026 |
| HARMONi-6 | 2 | #28 of 74 | May 31, 2026 |
| KRASCENDO-1 | 1 | #14 of 49 | Oct 25, 2026 |
| DeLLphi-305 | 1 | #25 of 86 | Oct 24, 2026 |
| CROWN | 1 | #34 of 36 | Oct 24, 2026 |
| LIBRETTO-432 | 1 | #26 of 53 | May 31, 2026 |
| WU-KONG28 | 1 | #9 of 29 | May 29, 2026 |
Ana I. Velázquez Mañana, MD, MSc, FASCO on RASolute 302
Standing ovation at #ASCO26 Plenary Session for RASolute 302 Daraxonrasib DOUBLES survival in pretreated pancreatic cancer The oncology community celebrates a much awaited advance for patients with pancreatic cancer 👏👏👏👏 https://t.co/qLJupZPR5S
🚨 Highlight of #ASCO26 RASolute 302 🚨 Daraxonrasib DOUBLES the median overall survival in pre-treated RAS G12 metastatic #PancreaticCancer mOS 13.2 mo vs. 6.6 mo with chemotherapy (HR 0.40) Published on @NEJM, looking forward to the presentation and discussion during https://t.co/HofXtgxdsC
Ana I. Velázquez Mañana, MD, MSc, FASCO on HARMONi-6
RT @StephenVLiu: HARMONi-6 from #ASCO26 plenary to @TheLancet: 1L ivonescimab + chemo vs tislelizumab/chemo in squamous NSCLC (n=761). Ivon…
RT @StephenVLiu: Dr. Shun Lu presents HARMONi-6 #ASCO26 plenary: first-line ivonescimab + chemo (carbo + pac) vs tislelizumab + chemo in sq…
Ana I. Velázquez Mañana, MD, MSc, FASCO on KRASCENDO-1
✨ PRACTICE CHANGING ✨ data from #ESMO26 Divarasib becomes the NEW Standard of Care for 2L KRAS G12C #LungCancer @FSkoulidis presents results from Krascendo 1 Divarasib significantly prolongs PFS and OS with a more tolerable safety profile https://t.co/JAcDUqlyDi
Ana I. Velázquez Mañana, MD, MSc, FASCO on DeLLphi-305
On Monday I told a patient with SCLC, this is the treatment plan today, but I’m hoping next week I can bring you better news from #ESMO26 👇 THIS is what we are here for! 🌟 PRACTICE CHANGING update for ES-SCLC: adding tarlatamb to maintenance durvalumab increases median OS by 58% (9mo) 🌟 Congrats to @sands_jacob and to all the DeLLphi-305 investigators! #ESMO26 #LCSM
Ana I. Velázquez Mañana, MD, MSc, FASCO on CROWN
👑 Updates on ctDNA data from the CROWN study, lorlatinib in ALK-fusion positive NSCLC at #ESMO26 🔹 TP53 mut. enriched on pts who experienced early progression 🔹 Baseline TP53 mut. associated with poor prognosis 🔹 Baseline detectable ctDNA and clearance at 4 and 24 wks prognostic of PFS #LCSM
Ana I. Velázquez Mañana, MD, MSc, FASCO on LIBRETTO-432
LIBRETTO-432 Adjuvant selpercatinib significantly prolonged EFS in early-stage RET+ NSCLC presented at #ASCO26 As nicely summarized by @christine_lovly broad NGS testing of early-stage, diagnosis in a population that doesn’t meet #LungCancer screening criteria, side effect https://t.co/de67VOIv0B
Ana I. Velázquez Mañana, MD, MSc, FASCO on WU-KONG28
🫁 #ASCO26 #LungCancer WU-KONG28: 1L Sunvozertinib in EGFR exon20ins NSCLC Compared to carbo/pemetrexed, sunvozertinib improved: 🔹mPFS 10.3 vs 7.5 mo (HR 0.65; 95% CI, 0.50 to 0.85) 🔹12mo PFS: 46.1% vs 26.7% 🔹ORR: 58.9% vs 31.1% 🔹mDOR 11.2 vs 7.1 mo ⬆️G3 or higher https://t.co/bPSBDsFeQ9
Ana I. Velázquez Mañana, MD, MSc, FASCO’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
Join us on Monday June 1st to wrap up #ASCO26 and be part of an engaging discussion on leadership development, networking, and building a value-aligned career! 🗓️ Monday June 1, 2026 at 6:30 PM RSVP: https://t.co/vj2yQrfrGn @RManochakian @triparnasen @lungoncdoc @ASridharMD https://t.co/XzjjMhiSVH
🫁 #ASCO26 Developmental Therapeutics - Targeted Agents Oral Abstract session is also a can't miss! 🔖 Novel CD56, DLL3, and B7-H3 targeting ADCs with promising activity in SCLC, NSCLC, and NECs, as well as three KRAS G12D agents! #LCSM #LungCancer #SCLC @ASCO @OncBrothers @OncoAlert
🫁 As you build your schedule for #ASCO26, don’t miss (or 🔖 bookmark to watch later) several interesting #LungCancer abstracts being presented outside the lung cancer tracks. Some highlights include ⬇️ 1️⃣ ctDNA Clinical Science Symposium: FLAME: osimertinib ± chemotherapy in EGFRm NSCLC with persistent ctDNA+ after 3 weeks on 1L osimertinib 2️⃣ #GlobalOnc #CareDelivery Clinical Science Symposium: Low-dose pembrolizumab + chemotherapy in 1L advanced NSCLC 3️⃣ CNS Tumors Oral Abstracts: ESAONA: asandeutertinib vs. osimertinib in 1L EGFRm NSCLC with brain metastases #LCSM #ASCO26 @ASCO @OncBrothers @OncoAlert
⬇️ This is what we are here for! May our thoracic oncology community continue to bring and share hope with many more patients and families! #WCLC26 https://t.co/XdGaO5k6KR
INTerpath-001 adjuvant Intismeran Autogene + Pembro vs Pembro for resected stage IIB-IV #Melanoma Impressive RFS and distant metastasis free survival improvement with a truly personalized and neoantigen-driven approach @ProfGLongMIA #ESMO26 @myESMO https://t.co/NQ1xb6krW8
Industry Payments
CMS Open Payments · 2025 general payments
$46,811 across 34 payments